Adaptimmune Therapeutics (ADAP) Earnings Date, Estimates & Call Transcripts $0.28 +0.01 (+5.17%) As of 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Adaptimmune Therapeutics Earnings Summary Upcoming Earnings DateMay. 13Before Market OpensEstimatedConsensus EPS (Mar. 24) -$0.17 Actual EPS (Mar. 24) -$0.26 Missed By -$0.09 Actual Revenue (Mar. 24) $3.22MAdaptimmune Therapeutics announced Q4 2024 earnings on March 24, 2025, reporting an EPS of -$0.26, which missed the consensus estimate of -$0.17 by $0.09. Quarterly revenue was reported to be $3.22 million, below analysts' expectations of $16.56 million. With a trailing EPS of -$0.27, Adaptimmune Therapeutics' earnings are expected to decrease next year, from ($0.14) to ($0.48) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Annual Report (10-K)ADAP Upcoming EarningsAdaptimmune Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get Adaptimmune Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptimmune Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataADAP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ADAP Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Adaptimmune Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.23-$0.10-$0.17Q2 20253-$0.18-$0.10-$0.13Q3 20253-$0.12-$0.08-$0.10Q4 20253-$0.12-$0.06-$0.09FY 202512($0.65)($0.34)($0.49) Adaptimmune Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/13/2025(Estimated)--------3/24/2025Q4 2024-$0.17-$0.26 -$0.09-$0.29$16.56M$3.22M8/12/2024Q2 2024-$0.27+$0.27$0.27$58.00M$128.23M5/15/2024Q1 2024-$0.16-$0.18 -$0.02-$0.18$4.40M$5.68M3/6/2024Q4 2023-$0.12-$0.24 -$0.12-$0.24$4.80M$0.23M11/8/2023Q3 2023-$0.20-$0.20--$0.20$5.00M$7.32M8/9/2023Q2 2023-$0.17-$0.21 -$0.04-$0.30$5.00M$5.13M5/12/2023Q1 2023-$0.19$0.01+$0.20$0.01$7.70M$47.60M Adaptimmune Therapeutics Earnings - Frequently Asked Questions When is Adaptimmune Therapeutics's earnings date? Adaptimmune Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based off last year's report dates. Learn more on ADAP's earnings history. Did Adaptimmune Therapeutics beat their earnings estimates last quarter? In the previous quarter, Adaptimmune Therapeutics (NASDAQ:ADAP) missed the analysts' consensus estimate of ($0.17) by $0.09 with a reported earnings per share (EPS) of ($0.26). Learn more on analysts' earnings estimate vs. ADAP's actual earnings. How can I listen to Adaptimmune Therapeutics's earnings conference call? The conference call for Adaptimmune Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Adaptimmune Therapeutics's conference call transcript? The conference call transcript for Adaptimmune Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Adaptimmune Therapeutics generate each year? Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded annual revenue of $178.03 million. How much profit does Adaptimmune Therapeutics generate each year? Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded net income of -$113.87 million. ADAP has generated -$0.27 earnings per share over the last four quarters. What is Adaptimmune Therapeutics's EPS forecast for next year? Adaptimmune Therapeutics's earnings are expected to decrease from ($0.14) per share to ($0.48) per share in the next year. More Earnings Resources from MarketBeat Related Companies CYRX Earnings ATXS Earnings AQST Earnings AURA Earnings ITOS Earnings ACB Earnings CMPX Earnings TSVT Earnings TERN Earnings AVIR Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings Will Make or Break the Stock's Comeback CrowdStrike Stock Nears Record High, Dip Ahead of Earnings?Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of Earnings This page (NASDAQ:ADAP) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADAP Stock Free ADAP Stock Alerts